---
title: "Accueil"
url: "https://everzom.com/"
description: "EVerZom is an exosome biotech company developing exosome therapeutics in digestive tissue healing, fistula and organ regeneration."
updated: "2024-08-01"
---

# Exosome biotech company

The most promising exosome therapeutics ever for digestive tissue healing and organ regeneration.

[More info](#mission)

## A key asset to the future health of an ageing population

Extracellular vesicles (EVs) or exosomes are subcellular entities released by cells. It is becoming widely known that exosomes are as effective as cell therapies for tissue regeneration, diseases such as stroke, heart failure, arthritis while being safer and more convenient for supply chains. Therefore, they are increasingly explored by many stakeholders.

## Everzom mission : *Unlocking the exosome revolution*

### An *innovation* platform

Founded in 2019, EverZom stands among the pioneers in exosome-based therapies, a significant revolution in the current therapeutic landscape of gene and cell therapies. Exosomes are biological nanoparticles secreted by cells that currently raise growing interest within the pharmaceutical industry due to their potent role in intercellular communication. They hold promising properties for treating a wide range of diseases with high unmet medical need. Winner of the European EIC Accelerator Program, EVerZom aims to become the leading biotech in this field.

The company has successfully developed an innovation platform protected by several patents, covering the entire technological value chain: cell sourcing, exosome generation, exosome loading, and formulation. By leveraging its platform, EVerZom aims to develop a pipeline of proprietary products in regenerative medicine, while establishing co-development partnerships in other therapeutic areas.

[Learn more](https://everzom.com/innovation-platform/)

### An *ambitious* pipeline

EVerZom is currently developing two drug candidates: one targeting the healing of digestive tissues, with Crohn’s fistula as the primary indication, and another focusing on organ regeneration, specifically the liver and kidney. Preclinical results have demonstrated a significant acceleration in the healing process and a reduction in inflammation and fibrosis. The market size for these indications is estimated at several billion euros.

[Learn more](https://everzom.com/therapeutic-programs/)

An ambitious pipeline

## Our latest scientific resources

###  [Exosome immunogenicity](https://everzom.com/2022/02/25/exosome-immunogenicity/)

To allow its use in humans and avoid side effects/risks or loss of potency, extracellular vesicles have to be tested to know more about their immunogenicity. As an example, the…

[Read](https://everzom.com/2022/02/25/exosome-immunogenicity/)

###  [Exosome stability and storage](https://everzom.com/2022/02/25/exosome-stability/)

The stability of extracellular vesicles (EVs) both before injection and after injection is a critical parameter to investigate. Once produced, extracellular vesicles have to be…

[Read](https://everzom.com/2022/02/25/exosome-stability/)

###  [Selection of the optimal cell source for extracellular vesicles production in regenerative…](https://everzom.com/2022/02/15/extracellular-vesicles-production-in-regenerative-medicine/)

Extracellular vesicles (EVs) are vesicles secreted by cells from several biogenesis pathways. Extracellular vesicles are currently developed for therapies mainly in regenerative…

[Read](https://everzom.com/2022/02/15/extracellular-vesicles-production-in-regenerative-medicine/)

## EVerZom latest news

Winner of the European EIC Accelerator program

EVerZom, announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition. This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry.

[More](https://cordis.europa.eu/project/id/190194936/fr)

## They support us